secwatch / observer
8-K filed November 30, 2022, 6:59 PM ET ticker SYRE CIK 0001636282
leadership confidence high sentiment neutral materiality 0.70

Aeglea Biotherapeutics appoints Jeffrey M. Goldberg as President and CEO

Spyre Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey M. Goldberg

President and Chief Executive Officer
SYRE · Spyre Therapeutics, Inc.
Effective
2022-11-29
Filed
November 30, 2022, 6:59 PM ET
On November 28, 2022, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.
Role change (interim)

Jim Kastenmayer

General Counsel and Corporate Secretary
SYRE · Spyre Therapeutics, Inc.
Effective
2022-11-29
Successor
Jeffrey M. Goldberg
Filed
November 30, 2022, 6:59 PM ET
In conjunction with the appointment of Mr. Goldberg, Jim Kastenmayer resigned from his position as the Company’s Interim Chief Executive Officer.
Appointed

Jeffrey M. Goldberg

Class III director
SYRE · Spyre Therapeutics, Inc.
Effective
2022-11-29
Filed
November 30, 2022, 6:59 PM ET
On November 28, 2022, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey M. Goldberg was appointed as President and Chief Executive Officer at Spyre Therapeutics, Inc..

Action
appointed
Role
President and Chief Executive Officer
Exact text from the filing
On November 28, 2022, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jim Kastenmayer resigned as General Counsel and Corporate Secretary at Spyre Therapeutics, Inc..

Action
resigned
Role
General Counsel and Corporate Secretary
Exact text from the filing
In conjunction with the appointment of Mr. Goldberg, Jim Kastenmayer resigned from his position as the Company’s Interim Chief Executive Officer.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey M. Goldberg was appointed as Class III director at Spyre Therapeutics, Inc..

Action
appointed
Role
Class III director
Exact text from the filing
On November 28, 2022, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.
View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-294899
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.